3-Hydroxy-3-(4-methyl-2,5-dioxo-2,5-dihydro-furan-3-yl)-propionic acid 10-[3,9-dimethyl-8-(3-methyl-4-oxo-pentyl)-1,7-dioxa-spiro[5.5]undec-2-yl]-3,7-dihydroxy-1-isopropyl-2-methoxy-6-methyl-5-oxo-undecyl ester

ID: ALA505512

Chembl Id: CHEMBL505512

PubChem CID: 440646

Max Phase: Preclinical

Molecular Formula: C41H66O13

Molecular Weight: 766.97

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  CO[C@H]([C@H](O)CC(=O)[C@@H](C)[C@@H](O)CC[C@@H](C)[C@@H]1O[C@]2(CC[C@@H](C)[C@H](CC[C@H](C)C(C)=O)O2)CC[C@@H]1C)[C@H](OC(=O)C[C@@H](O)C1=C(C)C(=O)OC1=O)C(C)C

Standard InChI:  InChI=1S/C41H66O13/c1-21(2)36(51-34(47)20-31(45)35-27(8)39(48)52-40(35)49)38(50-10)32(46)19-30(44)26(7)29(43)13-11-24(5)37-25(6)16-18-41(54-37)17-15-23(4)33(53-41)14-12-22(3)28(9)42/h21-26,29,31-33,36-38,43,45-46H,11-20H2,1-10H3/t22-,23+,24+,25-,26-,29-,31+,32+,33-,36+,37-,38+,41+/m0/s1

Standard InChI Key:  RFCWHQNNCOJYTR-IRCAEPKSSA-N

Alternative Forms

1. Parent:

   

   ALA505512

   TAUTOMYCIN

Molecule Features

Natural Product: Yes

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 766.97

Molecular Weight (Monoisotopic): 766.4503

AlogP: 4.79

#Rotatable Bonds: 20

Polar Surface Area: 192.19

Molecular Species: NEUTRAL

HBA: 13

HBD: 3

#RO5 Violations: 2

HBA (Lipinski): 13

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 13.63

CX Basic pKa: ┄

CX LogP: 6.01

CX LogD: 6.01

Aromatic Rings: ┄

Heavy Atoms: 54

QED Weighted: 0.11

Np Likeness Score: 1.76

References

1. McCluskey A, Sim AT, Sakoff JA..  (2002)  Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.,  45  (6): [PMID:11881984] [10.1021/jm010066k]

2. Liu W, Sheppeck JE, Colby DA, Huang HB, Nairn AC, Chamberlin AR..  (2003)  The selective inhibition of phosphatases by natural toxins: the anhydride domain of tautomycin is not a primary factor in controlling PP1/PP2A selectivity.,  13  (9): [PMID:12699763] [10.1016/s0960-894x(03)00105-7]

3. Colby DA, Liu W, Sheppeck JE, Huang HB, Nairn AC, Chamberlin AR..  (2003)  A new model of the tautomycin-PP1 complex that is not analogous to the corresponding okadaic acid structure.,  13  (9): [PMID:12699764] [10.1016/s0960-894x(03)00106-9]

4. Gupta V, Ogawa AK, Du X, Houk KN, Armstrong RW..  (1997)  A model for binding of structurally diverse natural product inhibitors of protein phosphatases PP1 and PP2A.,  40  (20): [PMID:9379439] [10.1021/jm960873x]

5. Li W, Luo Y, Ju J, Rajski SR, Osada H, Shen B..  (2009)  Characterization of the tautomycetin biosynthetic gene cluster from Streptomyces griseochromogenes provides new insight into dialkylmaleic anhydride biosynthesis.,  72  (3): [PMID:19191560] [10.1021/np8007478]

6. Zhang Q, Fan Z, Zhang L, You Q, Wang L..  (2021)  Strategies for Targeting Serine/Threonine Protein Phosphatases with Small Molecules in Cancer.,  64  (13.0): [PMID:34156850] [10.1021/acs.jmedchem.1c00631]

Source

Source(1):

• Scientific Literature